UY32935A - Polimorfos de pardoprunox - Google Patents

Polimorfos de pardoprunox

Info

Publication number
UY32935A
UY32935A UY0001032935A UY32935A UY32935A UY 32935 A UY32935 A UY 32935A UY 0001032935 A UY0001032935 A UY 0001032935A UY 32935 A UY32935 A UY 32935A UY 32935 A UY32935 A UY 32935A
Authority
UY
Uruguay
Prior art keywords
pardoprunox
polymorphes
benzoxazol
piperazinyl
hydrochloride
Prior art date
Application number
UY0001032935A
Other languages
English (en)
Inventor
Jeroen Van Rheenen
Teunissen Hendrik
Wilhelmus G H M Muijselaar
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of UY32935A publication Critical patent/UY32935A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Esta invención se refiere a un proceso novedoso para la preparación de clorhidrato de 7-(4-metil-1-piperazinil)benzoxazol-2(3H)-ona, un agonista del receptor de la dopamina-D2 parcial y un agonista del receptor de la serotonina 5-HT1A total;Clorhidrato de 7-(4-metil-1-piperazinil)benzoxazol-2(3H)-ona
UY0001032935A 2009-10-12 2010-10-06 Polimorfos de pardoprunox UY32935A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09172802 2009-10-12

Publications (1)

Publication Number Publication Date
UY32935A true UY32935A (es) 2011-05-31

Family

ID=42028109

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001032934A UY32934A (es) 2009-10-12 2010-10-06 Monohidrato de pardoprunox
UY0001032935A UY32935A (es) 2009-10-12 2010-10-06 Polimorfos de pardoprunox

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001032934A UY32934A (es) 2009-10-12 2010-10-06 Monohidrato de pardoprunox

Country Status (9)

Country Link
US (2) US20110251214A1 (es)
EP (1) EP2488181A1 (es)
JP (1) JP2013507420A (es)
AR (2) AR078556A1 (es)
AU (1) AU2010305834A1 (es)
CA (1) CA2777305A1 (es)
TW (2) TW201118089A (es)
UY (2) UY32934A (es)
WO (2) WO2011045267A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
US7786126B2 (en) * 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist

Also Published As

Publication number Publication date
UY32934A (es) 2011-05-31
TW201118089A (en) 2011-06-01
US20110251214A1 (en) 2011-10-13
WO2011045267A1 (en) 2011-04-21
TW201118090A (en) 2011-06-01
US20110086862A1 (en) 2011-04-14
AR078556A1 (es) 2011-11-16
JP2013507420A (ja) 2013-03-04
AR078555A1 (es) 2011-11-16
CA2777305A1 (en) 2011-04-21
EP2488181A1 (en) 2012-08-22
AU2010305834A1 (en) 2012-06-07
WO2011045270A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
CO6920295A2 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2
CO6410295A2 (es) Derivados de indol como antagonistas del receptor crth2
ECSP14020478A (es) Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
CR10849A (es) Derivados de benzamida como agonistas del receptor ep4
DOP2012000135A (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
TN2011000673A1 (en) Bace inhibitors
CL2013003686A1 (es) Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña.
CR11742A (es) Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
BRPI1013777A2 (pt) compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.
CR20120265A (es) Combinaciones de un antagonista de los receptores muscarínicos y un agonista del adreno-receptor beta-2
DK2735063T3 (da) Compton-lyskilder med høj strøm og smal båndvidde gennem udvidede laser-elektronstråleinteraktioner
GT200800052A (es) Compuestos triciclicos utiles como agonistas de recepciones de oxitocina
CL2012000272A1 (es) Proceso para la preparacion de (9-diclorometileno-1,2,3,4-tetrahidro-1,4-metano-naftalen-5-il)-amida del acido 3-difluorometil-1-metil-1h-pirazol-4-carboxilico; y los compuestos intermediarios considerados.
ES2572368T3 (es) Tratamiento de la artrosis
IN2012DN01929A (es)
SMT201400070B (it) Impiego della 7-cloro-n,n,5-trimetil-4-osso-3-fenil-3,5-diidro-4H-piridazino[4,5-B]indolo-1-acetamide come un biomarcatore di livelli del recettore periferico di benzo-diazepine
UY32935A (es) Polimorfos de pardoprunox
ECSP12011781A (es) Procesos para la preparación de 2-(1-feniletil) - isoindolin-1-ona
SV2009002893A (es) Procedimientos novedosos para la preparacion de derivados de piperacinil y diazapanil benzamida ref. prd2560
MX2011008458A (es) Metodos para preparar agonistas y antagonistas del receptor s1p.
UY34535A (es) Nuevo uso terapéutico de antagonistas del receptor p75.
CR20120288A (es) 2-amino-9-[4-4(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d] primidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo
UY33210A (es) DERIVADOS DE PIRAZOLO-[5, 1b]-OXAZOL COMO ANTAGONISTAS DE LOS RECEPTORES DE CRF-1

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190219